title: Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
abstract: OBJECTIVE
  To evaluate, in a screening population, the impact of tumor volume and prostate volume on prostate-specific antigen (PSA) velocity (PSAV) and to find predictors of biochemical failure after radical prostatectomy. Longitudinal PSA changes in men with prostate cancer have been reported to be significantly different from those without prostate cancer.
  
  
  METHODS
  PSAV was assessed in 102 men undergoing radical retropubic prostatectomy. The pathologic findings of specimens obtained at radical retropubic prostatectomy and pelvic lymph node dissection were analyzed separately for all patients.
  
  
  RESULTS
  The median preoperative PSA in the 102 patients was 6.4 ng/mL, the median prostate volume was 32.8 cm3, and the median tumor volume was 1.27 cm3. The PSAV correlated significantly with tumor volume (P <0.05) but not with prostate volume (P = 0.142). The median tumor volume in men with biochemical progression after radical retropubic prostatectomy was 2.55 cm3 versus 0.94 cm3 in men who were free of disease 5 years after surgery. The median PSAV in the year before diagnosis in men with relapse after radical prostatectomy was 1.98 ng/mL/yr versus 1.05 ng/mL/yr in men who had no evidence of disease.
  
  
  CONCLUSIONS
  The results of our study have shown that the main factor contributing to the PSAV in patients with prostate cancer is cancer load and that prostate volume is not significantly associated with the PSAV. Men with a PSAV of more than 2 ng/mL/yr in the year before cancer diagnosis are at a high risk of relapse. The PSAV may be helpful in identifying patients with small tumors and thus increase the detection rate of potentially curable prostate cancers.
authors.affiliation: Department of Urology, Medical University of Innsbruck, Innsbruck, Austria. andreas.p.berger@uibk.ac.at
authors.forename: Andreas P
authors.initials: AP
authors.lastname: Berger
authors.forename: Martina
authors.initials: M
authors.lastname: Deibl
authors.forename: Alexander
authors.initials: A
authors.lastname: Strasak
authors.forename: Jasmin
authors.initials: J
authors.lastname: Bektic
authors.forename: Alexandre
authors.initials: A
authors.lastname: Pelzer
authors.forename: Hannes
authors.initials: H
authors.lastname: Steiner
authors.forename: Robert
authors.initials: R
authors.lastname: Spranger
authors.forename: Gernot
authors.initials: G
authors.lastname: Fritsche
authors.forename: Georg
authors.initials: G
authors.lastname: Bartsch
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Horninger
mesh_terms: D000328:Adult; D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000453:epidemiology*; D009929:Organ Size; D011300:Preoperative Care; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology* / Q000601:surgery; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D017430:Prostate-Specific Antigen